Combination therapy for EBV-related diseases
Part of Infections clinical trials.
This trial tests a combination of drugs (PD-1 inhibitor, tenofovir, chidamide, and lenalidomide) to treat diseases caused by the Epstein-Barr virus (EBV). The goal is to see if this combination can reduce the virus and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an EBV-related disease, such as infectious mononucleosis or chronic active EBV infection.
- Your EBV levels are high (at least 10,000 copies per milliliter of blood).
- You are 75 years old or younger and are generally able to care for yourself (ECOG score 2 or less).
- You are expected to live at least 3 more months.
- You do not have severe liver, kidney, or bone marrow problems, and you have not had recent heart issues or serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of four drugs (an immunotherapy called a PD-1 inhibitor, an antiviral drug called tenofovir, and two other targeted therapies) for people whose EBV-related lymphoma has come back or not improved after treatment. The goal is to see if this combination can control the disease and help patients live longer.
This is an early-stage study testing a new immune-based treatment for people with conditions caused by the Epstein-Barr virus (EBV), such as chronic active EBV or post-transplant lymphoproliferative disease. The study aims to see if the treatment is safe and can help control the disease.
This trial tests two drugs, golidocitinib and selinexor, given together to treat chronic active Epstein-Barr virus disease (CAEBVD). The goal is to see if this combination can help control the disease better than current options.
This study tests a new mRNA-based immunotherapy for diseases caused by the Epstein-Barr virus (EBV), such as certain cancers and conditions after a stem cell transplant. The treatment aims to help your immune system fight the virus and the disease.
This trial tests nivolumab (an immune therapy) for people with EBV-positive lymphoma or EBV-driven immune/lymph conditions. It may help shrink tumors or control the disease when standard treatments have not worked or are not suitable.
This Phase 1 study tests an immune-cell therapy made to recognize EBV (a common virus) in people whose lymphoma contains EBV. It may help control EBV-driven cancers, especially when standard treatment isn’t working or can’t be used.
Hear when a new Epstein-Barr Virus (EBV) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.